-
Role of the bone marrow vascular niche in chemotherapy for MLL-AF9-induced acute myeloid leukemia
Acute myeloid leukemia (AML) represents a significant challenge in cancer treatment, primarily due to the resilience of leukemia stem cells (LSCs) within the bone marrow (BM) niche against conventional chemotherapy,…
-
Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins
Myeloproliferative neoplasms (MPNs) are clonal hematologic stem cell disorders characterized by excessive output of myeloid cells and an increased risk of leukemic transformation. Current management of MPNs is mainly focused…
-
Effects of genetic polymorphisms on methotrexat levels and toxicity in Chinese patients with acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a hematological malignancy affecting both children and adults, with methotrexate (MTX) being a cornerstone of therapy. However, variability in efficacy and toxicity poses challenges, partly…
-
2024 CASH丨Professor RongFu : Progress in the Study of Hematological Toxicity Related to CAR-T Therapy
Immunotherapy has recently emerged as a focal area in the research of hematologic oncology. The advancement of genetic engineering and molecular biology, coupled with deeper insights into the mechanisms of cancer, has led to the widespread clinical adoption of Chimeric Antigen Receptor T Cell (CAR-T) therapy. This approach has demonstrated remarkable efficacy in treating refractory…
-
Professor Jun Zhu: Focus on the unmet needs of diffuse large B-cell lymphoma (DLBCL) and provide personalized diagnosis and treatment for patients
Diffuse large B-cell lymphoma (DLBCL) is a typical B-cell lymphoma, characterized by high invasiveness and heterogeneity. After standard first-line treatment, some patients still face relapse/refractory issues and relatively poor prognosis. Recently, the “7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematology Oncology and Immunology Summit Forum” was successfully held in Beijing from March…
-
Professor Hu Zhou: Rational selection of treatment strategies to improve the quality of life for patients with tumor-related thrombocytopenia
Thrombocytopenia is a common hematologic adverse reaction to cancer treatment, which can increase the risk of bleeding, prolong hospitalization, increase medical costs, and in severe cases, lead to death. Recently, the “7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematology Oncology and Immunology Summit Forum”, hosted by the Chinese Society of Immunology Hematology…
-
Professor Jun Ma: Development in the Field of Hematologic Tumors Advances by Leaps and Bounds, Autonomous Innovation Facilitates the Improvement of Diagnosis and Treatment
The “7th Beijing Thrombosis and Hemostasis Conference of the Chinese Society of Immunology Hematology Branch” and the “5th Beijing Hematologic Tumor and Immunology Summit Forum” sponsored by the Chinese Society of Immunology Hematology Branch and hosted by the National Clinical Research Center for Hematologic Diseases- Peking University Institute of Hematology and Peking Union Medical College…
-
Professor Xiaohui Zhang: From running behind to leading the world in hematopoietic stem cell transplantation in China | The 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association
As spring arrives, the 13th National Conference on Hematopoietic Stem Cell Transplantation of the Chinese Medical Association, hosted by the Chinese Medical Association and organized by the National Clinical Research Center for Hematologic Diseases-Peking University Institute of Hematology, was grandly held in Beijing from March 1st to 2nd. This conference focused comprehensively on hematopoietic stem…
Connecting Medical Expertise through Media